Back

Patient knowledge about risk factors, achievement of target values and guideline adherent secondary prevention 12 months after acute myocardial infarction. Results of the prospective GULLIVE-R study.

29 August 2022 (16:15 - 16:45)
Organised by:
Congress Presentation Part of: Treatment of coronary artery disease Pharmacotherapy ESC Professional Premium Access ESC Congress 2022

About the speaker

Photo
Professor Uwe Zeymer

Foundation Institute for Heart Attack Research, Ludwigshafen (Germany)

5 More presentations in this session

Presentation thumbnail
Infarct size, inflammatory burden and admission hyperglycemia in diabetic patients with acute myocardial infarction treated with SGLT2-inhibitors: a multicenter international registry.
Doctor A. Sansonetti (Bologna, IT)
Abstract Slides
Presentation thumbnail
The effect of P2Y12 inhibitor monotherapy according to bleeding risk: a systematic review and meta-analysis
Ms E. Woelders (Nijmegen, NL)
Abstract Slides
Presentation thumbnail
Positive predictive value of the crusade score for bleeding events in patients with acute coronary syndromes on dual antiplatelet therapy with acetylsalicylic acid and clopidogrel
Doctor J. Monteiro (Vila Real, PT)
Abstract Slides
Presentation thumbnail
To pretreat or not no pretreat with dual antiplatelet therapy in non-ST elevation acute coronary syndrome patients: that is the question.
Doctor D. Abella Vallina (Burgos, ES)
Abstract Slides
Presentation thumbnail
Effect of alirocumab added to high-Intensity statin therapy on endothelial function in patients with acute myocardial infarction: A sub-study of the randomized placebo-controlled PACMAN-AMI trial
Doctor E. Rexhaj (Bern, CH)
Abstract Slides

Access the full session

Session thumbnail
Treatment of coronary artery disease

The Event

Event poster

ESC Congress 2022

29 August 2022 16:15 CET

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources